ABSTRACT -In our previous study, we demonstrated that the initial hepatic injury caused by bromobenzene (BB) was no longer detected in rats despite subsequent dosing, indicating that the liver acquired resistance to BB-induced hepatotoxicity. In this experiment, microarray analysis was conducted to characterize this resistance. The liver samples for the analysis utilized were obtained from previous experiments where F344 rats were treated intraperitoneally with BB (150 mg/kg). At 24 hr post-dose, hepatic injury was confirmed by monitoring the AST values and then the rats were maintained at the same dosing regimen for an additional 8 days. The gene expression profiles of the BB-treated rat livers were compared with a vehicle-treated group by Affymetrix RG_U34A arrays. As results, a decreased expression level of CYP3A9 and an increased expression level of GST Yc2 and glutathione peroxidase (GPX) were detected. These changes indicated suppression of the phase I reaction and induction of the phase II reaction (glutathione conjugation). Increased expression levels of epoxide hydrolase (EH) and NAD(P)H:quinone oxidoreductase (NQO1) also suggested the involvement of EH-and NQO1-mediated hydrolysis other than glutathione conjugation with resistance in the phase II reaction. Moreover, an increased expression level of abcc3 (multidrug resistance protein 3; Mrp3) was significantly noted. Based on the present findings, it was suggested that Mrp3 in the phase III reaction (drug elimination) contributed to the resistance to BB hepatotoxicity in addition to the suppression of the phase I reaction (metabolic activation) and the induction of the phase II reaction (detoxification). Among them, the factors which contributed most were considered to be the increased GST Yc2 and Mrp3, based on the degree of the gene expression changes.
INTRODUCTION
We have previously demonstrated that BB-elicited initial insult was no longer detected, even though further treatment was continuously applied after the initial insult, suggesting that further treatment provided resistance to the BB hepatotoxicity. CYP involved in the metabolic activation of BB decreased and the GST involved in the detoxification of BB increased. The changes of CYP and glutathione conjugation indicated decreased the active metabolites and accelerated detoxification, respectively, demonstrating the suppressive alteration of the BB-induced toxicity (Tanaka et al., 2005) . It has been reported that decreased CYP or increased glutathione reductase activities contributed to an impaired sensitivity to the hepatotoxicity resulting from repeated APAP treatment (Strubelt et al., 1979; O'Brien et al., 2000) , which supported our results. Regarding resistance to styrene-induced hepatotoxicity, however, factors other than the metabolic inactivation of styrene were considered to be attributable to the resistance (Mahler et al., 1999) . In our previous study, it was suggested that factors other than the decreased CYP and the increased GST activities contributed to the resistance. In the present study, microarray analysis was conducted in order to examine these factors.
MATERIALS AND METHODS

Microarray analysis
Parts of the livers obtained from our previous
Correspondence: Kohji TANAKA (E-mail: kjtana@sankyo.co.jp) study (Tanaka et al., 2005) were utilized in this study. The liver samples from the rats of Groups 1 (control), 2 (the initial liver injury) and 3 (no injury) were homogenized with the RLT buffer supplied in the RNeasy Mini Kit (QIAGEN, Valencia, CA, USA), and the total RNA was isolated according to the manufacturer's instructions. Microarray analysis was performed according to the Affymetrix standard protocol. Briefly, a total RNA of 5 μg prepared from the individual rat liver samples was used for cDNA synthesis using a T7-(dT) 24 primer (Amersham Biosciences, Tokyo, Japan). A biotin-labeled cRNA mix was transcribed using a BioArray High Yield RNA Transcription Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA). Every biotin-labeled cRNA target sample (approximately 10 μg) was individually hybridized to a GeneChip ® RG_U34A Array (Affymetrix Inc., Santa Clara, CA, USA) at 45°C for 16 hr. GeneChip ® was washed and stained using a Fluidics Station (Affymetrix Inc.) and scanned with a GeneArray ® Scanner (Affymetrix Inc.). The microarray image data obtained from the rat livers were analyzed with Microarray Suite Ver. 5.0 (Affymetrix Inc.).
Statistical analysis
The data were analyzed by the F-test to evaluate the homogeneity of variance. If the variance was homogeneous, Student's t-test was applied. If the variance was heterogeneous, Aspin-Welch's t-test was performed. A significance level of p < 0.01 or p < 0.05 was considered acceptable.
RESULTS
The GeneChip analysis on the livers from Groups 1, 2 and 3 was carried out, and the data were processed statistically against Group 1. According to the results, there were 16 and 9 for up-regulated and down-regulated genes, respectively, in the common significant changes between Groups 2 and 3. As for up-regulated genes, the expression levels of GST Yc2 and glutathione peroxidase (GPX) in the phase II reaction in both Groups 2 and 3 were approximately 7 and 4 times greater than those in Group 1, respectively. Increased expression levels of epoxide hydrolase (EH) and NAD(P)H: menadione oxidoreductase, also known as NAD(P)H: quinone oxidoreductase 1 (NQO1), were observed 2 and 3 times in both Groups 2 and 3, respectively. The expression level of abcc3, also known as multidrug resistance protein 3 (Mrp3), increased approximately 6 times in both groups. On the other hand, a decreased probe for the expression level of CYP3A9 in both Groups 2 and 3 was noted approximately 0.4 times compared to Group 1. There were no remarkable differences in the intensity of these changes between Groups 2 and 3 ( Table 1) .
The number of genes which showed significant changes in only Group 2 included 21 for up-regulated genes and 7 for down-regulated genes. Among the upregulated genes, the expression levels of GST Pi, gamma-glutamylcysteine synthetase (γGCS), glutathione cysteine ligase and glutathione reductase (GR) increased approximately 7, 2, 4 and 2 times compared to Group 1. The expression levels of these genes in Group 3 tended to increase, but not to be statistically significant ( Table 2 ). The number of genes which were significant in Group 3 alone were 3 for up-regulated and 2 for down-regulated (Table 3) .
DISCUSSION
The resistance to BB-elicited hepatotoxicity by repeated treatments of BB was characterized by a microarray.
Among the genes whose expression levels were significantly changed from those of Group 1, genes whose expression levels changed commonly in both Groups 2 and 3 were considered to be the essential factors responsible for the resistance. The number of upregulated genes common to both Groups 2 and 3 was 16, which included drug-metabolizing enzymes, and in particular phase II reactions. Up-regulated GST Yc2 and GPX were observed, suggesting augmented detoxification of BB by glutathione conjugation. The number of down-regulated genes was 9, of which the most noteworthy one was the decreased CYP3A9. This finding suggested the suppression of metabolic activation for BB. Thus, these findings supported the results at the protein levels reported previously (Tanaka et al., 2005) .
This microarray analysis, furthermore, revealed up-regulation of EH and NQO1 in both Groups 2 and 3. BB subjected to CYP-mediated epoxidation yields two active metabolites, 2,3-epoxide and highly electrophilic 3,4-epoxide (Minami et al., 2005) . In an alternative pathway in phase II reactions other than glutathione conjugation, the epoxides are hydrolyzed by microsomal epoxide hydrolase and CYPs, and the resulting bromophenol can be oxidized to hydroquinones and conjugated to GSH (Heijne et al., 2004 : Williams, 2006 . The EH up-regulation suggested that increased EH-mediated hydrolysis in addition to the glutathione conjugation in the phase II reaction participated in the resistance. The expression level of NQO1 increased significantly in Groups 2 and 3. NQO1 is a flavoprotein that catalyzes the metabolic detoxification of quinones, which are also formed in the biotransformation of BB (Jaiswal, 2000; Long et al., 2000; McMillian et al., 2004) . It was suggested, therefore, that EH-and NQO1-mediated hydrolysis in addition to glutathione conjugation was enhanced in the liver along with the resistance.
Importantly, expression level of abcc3 (Mrp3) increased in both Groups 2 and 3. The MRPs are a sub- (Konig et al., 1999; Roelofsen et al., 1997; Tian et al., 2004) , and drug elimination via transporters including MRPs is defined as a phase III reaction followed by phase I and phase II drug-metabolizing reactions (Cherrington, et al., 2002; Wagner et al., 2005) . Mrp3 expression is very low in normal rat and human livers (Ruiz et al., 2006; Soroka et al., 2001) . Up-regulation of Mrp3 is noted in animals with obstructive cholestasis and is considered to compensate for impaired canalicular Mrp2 function (Donner and Keppler, 2001; Hirohashi et al., 1998) . Mrp3 expression is also induced by the administration of phenobarbital (Ogawa et al., 2000) . There were no remarkable differ- ences in these changes in the up-regulation level of Mrp3 between Groups 2 and 3. Taken together, these results indicated that the increased phase III (Mrp3) reaction in addition to the suppressed phase I (CYP) reaction and the increased phase II (glutathione conjugation, EH-mediated hydrolysis and quinone metabolism) reaction was attributable to the resistance. Among these reactions, the factors which contributed most were considered to be the increased GST Yc2 and Mrp3, based on the degree of the changes.
Only in Group 2, up-regulation of genes for GST Pi, γGCS, glutathione cysteine ligase and GR in the phase II reaction was significantly noted compared to Group 1. These changes except for AFAR suggested that glutathione conjugation and metabolism were augmented in Group 2. On the other hand, the expression level of these genes in Group 3 tended to increase, but were not statistically significant in Group 1. Based on the present findings, there were qualitatively the same gene expression profiles in phases I, II and III, but there were quantitatively different ones in the glutathione conjugation for the phase II reaction. In other words, the resistance against toxicity by 150 mg/kg BB in Group 2 indicated more active gene expression in glutathione conjugation than that in Group 3. Differences other than the gene expression profiles between Groups 2 and 3 included only the presence or absence of hepatic initial injury by a single dose of BB. The quantitatively different profiles may represent the influence of the initial insult or the individual variability of sensitivity to BB hepatotoxicity.
In conclusion, microarray analysis on livers with resistance to BB hepatotoxicity demonstrated decreased phase I (CYP) and increased phase II (glutathione conjugation) reactions at the protein levels reported previously. The analysis revealed other phase II reactions such as EH-and NQO1-mediated hydrolysis, and increased Mrp3 drug transporter. Thus, the results in this study suggest that not only phase I and phase II but also phase III reactions contributed to the resistance. Among these reactions, the factors which contributed most were considered to be the increased GST Yc2 and Mrp3, based on the degree of the changes. 
